Strategic partnerships Novartis México is actively expanding its collaboration footprint through university and hospital partnerships, as evidenced by multiple June 2026 announcements involving USC, Keck School of Medicine, and Hull University Teaching Hospitals NHS Trust. This indicates a sales opportunity for solutions that support collaborative research, clinical trials, data sharing, and molecular imaging services.

Clinical pipeline Recent news highlights the launch and advancement of therapies like Pluvicto for prostate cancer, signaling ongoing investment in oncology and radioligand therapy. This presents opportunities to engage in companion diagnostic services, patient support programs, supply chain optimization, and specialized manufacturing capabilities.

Digital backbone Novartis México utilizes a mix of enterprise tools (SAP Commerce Cloud, Microsoft SharePoint, Amazon S3, GrowthBook) and data/AI tech (spaCy), suggesting receptivity to software that improves regulatory compliance, data analytics, e-commerce enablement, and secure information governance in a regulated pharmaceutical context.

Regulatory risk The brand actively communicates anti-fraud measures and privacy rights, indicating emphasis on compliance, privacy, and risk management. This creates opportunities to offer robust vendor risk assessments, privacy-by-design consulting, and secure patient data handling solutions for commercial and clinical operations.

Market positioning With mid-sized scale in Mexico (501–1000 employees) and revenue indicators in the millions, Novartis México sits between regional affiliates and global hubs, suggesting a need for scalable, localized support services—such as regulatory affairs localization, pharmacovigilance, and logistics optimization—to strengthen market presence and speed to market.